bmi semaglutide Allocation of According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA Frontiers | Efficacy and safety

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes

New analysis suggests that negotiated pricing still falls short of achieving cost neutrality if GLP-1 drug coverage expands to include weight management.

The trials will provide data on the potential disease-modifying effects of semaglutide and will be important in evaluating its utility in the treatment of early-stage symptomatic AD

In late 2025, a seemingly narrow advertising dispute told a much bigger story about the GLP-1 market

RYGB produces higher early postprandial increases in GLP-1 and glucose than OAGB, demonstrating that procedural differences can influence gut hormone and glucose responses.

GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity